187 related articles for article (PubMed ID: 12461013)
21. Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.
Pfaller MA; Flamm RK; Mendes RE; Streit JM; Smart JI; Hamed KA; Duncan LR; Sader HS
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373807
[TBL] [Abstract][Full Text] [Related]
22. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
Finch RG
Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
[TBL] [Abstract][Full Text] [Related]
23. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients.
Rolston KVI; Jamal MA; Nesher L; Shelburne SA; Raad I; Prince RA
Int J Antimicrob Agents; 2017 Apr; 49(4):416-421. PubMed ID: 28257904
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
Fritsche TR; Stilwell MG; Jones RN
Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
[TBL] [Abstract][Full Text] [Related]
26. Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.
Farrell DJ; Flamm RK; Sader HS; Jones RN
Antimicrob Agents Chemother; 2014 Jul; 58(7):3882-8. PubMed ID: 24777091
[TBL] [Abstract][Full Text] [Related]
27. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
[TBL] [Abstract][Full Text] [Related]
28. [Antimicrobial spectrum of ceftaroline. In vitro activity against methicillin-resistant staphylococci].
Cercenado E; Morosini MI
Enferm Infecc Microbiol Clin; 2014 Mar; 32 Suppl 2():8-14. PubMed ID: 24702973
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.
Sultan T; Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
31. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Pfaller MA; Flamm RK; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
[TBL] [Abstract][Full Text] [Related]
32. Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2003 Oct; 47(2):435-40. PubMed ID: 14522519
[TBL] [Abstract][Full Text] [Related]
33. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
35. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.
Flamm RK; Sader HS; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2012 Jun; 56(6):2933-40. PubMed ID: 22470115
[TBL] [Abstract][Full Text] [Related]
36. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
[TBL] [Abstract][Full Text] [Related]
37. Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019.
Huband MD; Thompson JD; Gurung ND; Liu Q; Li L; Zhang J; Streit JM; Castanheira M
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0139721. PubMed ID: 34633850
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.
Hebeisen P; Heinze-Krauss I; Angehrn P; Hohl P; Page MG; Then RL
Antimicrob Agents Chemother; 2001 Mar; 45(3):825-36. PubMed ID: 11181368
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.
Azoulay-Dupuis E; Bédos JP; Mohler J; Schmitt-Hoffmann A; Schleimer M; Shapiro S
Antimicrob Agents Chemother; 2004 Apr; 48(4):1105-11. PubMed ID: 15047508
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole.
Chung M; Antignac A; Kim C; Tomasz A
Antimicrob Agents Chemother; 2008 Aug; 52(8):2709-17. PubMed ID: 18505853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
